NASDAQ · ICCM
Healthcare · Medical - Devices
$1.54
Down-$0.27 (-17.53%)
Updated Oct 6, 2026, 11:28 PM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ICCM
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
ICCM closed at $1.54 after 20 trading sessions, down 30.32% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $1.59 | $1.6052 | $1.47 | $1.54 | 159.27K |
| Oct 2, 2026 | $1.73 | $1.79 | $1.55 | $1.57 | 311.69K |
| Oct 1, 2026 | $1.65 | $1.725 | $1.61 | $1.69 | 157.1K |
| Sep 30, 2026 | $1.63 | $1.82 | $1.60 | $1.615 | 321.22K |
| Sep 29, 2026 | $1.65 | $1.69 | $1.56 | $1.59 | 192.37K |
| Sep 28, 2026 | $1.71 | $1.77 | $1.60 | $1.63 | 87.13K |
| Sep 25, 2026 | $1.80 | $1.8999 | $1.65 | $1.73 | 116.39K |
| Sep 24, 2026 | $1.87 | $1.94 | $1.71 | $1.73 | 91.08K |
| Sep 23, 2026 | $1.94 | $2.0199 | $1.83 | $1.87 | 85.55K |
| Sep 22, 2026 | $1.9813 | $2.04 | $1.94 | $1.95 | 101.08K |
| Sep 21, 2026 | $1.99 | $2.08 | $1.95 | $1.95 | 70.96K |
| Sep 18, 2026 | $2.0591 | $2.0591 | $1.95 | $1.96 | 80.27K |
| Sep 17, 2026 | $2.11 | $2.16 | $1.96 | $1.99 | 159.13K |
| Sep 16, 2026 | $2.06 | $2.14 | $2.02 | $2.06 | 81.47K |
| Sep 15, 2026 | $2.12 | $2.14 | $2.04 | $2.05 | 95.37K |
| Sep 14, 2026 | $2.21 | $2.21 | $2.09 | $2.09 | 73.8K |
| Sep 11, 2026 | $2.13 | $2.50 | $2.10 | $2.21 | 211.9K |
| Sep 10, 2026 | $2.08 | $2.20 | $2.06 | $2.14 | 278.95K |
| Sep 9, 2026 | $2.21 | $2.21 | $2.10 | $2.11 | 67.12K |
| Sep 8, 2026 | $2.25 | $2.25 | $2.14 | $2.21 | 54K |
The latest Smart Investors Daily articles mentioning ICCM.
Company
Market Activity
Research & News
ICCM research
Company profile and research snapshot.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 14, 2026 | Maxim Group | Buy | — |
| Oct 7, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 15, 2025 | HC Wainwright & Co. | Buy | — |
| May 29, 2025 | HC Wainwright & Co. | Buy | — |
| Mar 28, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 18, 2026
Icecure Medical (NASDAQ:ICCM) released second-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial
Yahoo · Sep 11, 2026
ICCM's NMPA approval for ProSense opens China to commercialization, expanding its global regulatory footprint and long-term revenue opportunity.
Yahoo · Sep 10, 2026
IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has received approval, as a Class III medical device, from China's National Medical Products Administration ("NMPA") for its ProSense® system and associated cryoprobes.
Benzinga · Sep 10, 2026
IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ICCM.
